Aarhus University Seal / Aarhus Universitets segl

Nitrosatable drug exposure during pregnancy and risk of stillbirth

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Nitrosatable drug exposure during pregnancy and risk of stillbirth. / Thomsen, Anne Marie L.; Liew, Zeyan; Riis, Anders Hammerich; Stayner, Leslie Thomas; Ramlau-Hansen, Cecilia Høst; Sigsgaard, Torben; Olsen, Jørn.

In: Pharmacoepidemiology and Drug Safety, Vol. 28, No. 9, 01.09.2019, p. 1204-1210.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Thomsen, AML, Liew, Z, Riis, AH, Stayner, LT, Ramlau-Hansen, CH, Sigsgaard, T & Olsen, J 2019, 'Nitrosatable drug exposure during pregnancy and risk of stillbirth', Pharmacoepidemiology and Drug Safety, vol. 28, no. 9, pp. 1204-1210. https://doi.org/10.1002/pds.4867

APA

Thomsen, A. M. L., Liew, Z., Riis, A. H., Stayner, L. T., Ramlau-Hansen, C. H., Sigsgaard, T., & Olsen, J. (2019). Nitrosatable drug exposure during pregnancy and risk of stillbirth. Pharmacoepidemiology and Drug Safety, 28(9), 1204-1210. https://doi.org/10.1002/pds.4867

CBE

MLA

Thomsen, Anne Marie L. et al. "Nitrosatable drug exposure during pregnancy and risk of stillbirth". Pharmacoepidemiology and Drug Safety. 2019, 28(9). 1204-1210. https://doi.org/10.1002/pds.4867

Vancouver

Thomsen AML, Liew Z, Riis AH, Stayner LT, Ramlau-Hansen CH, Sigsgaard T et al. Nitrosatable drug exposure during pregnancy and risk of stillbirth. Pharmacoepidemiology and Drug Safety. 2019 Sep 1;28(9):1204-1210. https://doi.org/10.1002/pds.4867

Author

Thomsen, Anne Marie L. ; Liew, Zeyan ; Riis, Anders Hammerich ; Stayner, Leslie Thomas ; Ramlau-Hansen, Cecilia Høst ; Sigsgaard, Torben ; Olsen, Jørn. / Nitrosatable drug exposure during pregnancy and risk of stillbirth. In: Pharmacoepidemiology and Drug Safety. 2019 ; Vol. 28, No. 9. pp. 1204-1210.

Bibtex

@article{9faa3d960b224ee8b9e3724400f7d257,
title = "Nitrosatable drug exposure during pregnancy and risk of stillbirth",
abstract = "Purpose: Nitrosatable drugs can react with nitrite in the stomach and form N-nitroso compounds. Exposure to nitrosatable drugs has been associated with congenital malformations and preterm birth, but use during pregnancy as a cause of fetal death is not well-known. We examined if prenatally nitrosatable drug use is associated with risk of stillbirth. Methods: A nationwide cohort was conducted using 554 844 women with singleton and first recorded pregnancies regardless of previous pregnancy history from the Danish Medical Birth Register from 1996 to 2015. Exposure was recorded by use of the Danish National Prescription Register and defined as women who had redeemed a prescribed nitrosatable drug in the first 22 weeks of pregnancy. The reference group was women with no redeemed prescribed nitrosatable drug in this time period. We categorized nitrosatable drugs as secondary amines, tertiary amines, and amides. Cox hazard regression was used to estimate crude and adjusted hazard ratios (aHRs) with 95{\%} confidence intervals (CIs) for stillbirth. Results: Among the 84 720 exposed women, 348 had a stillbirth compared with 1690 stillbirths among the 470 124 unexposed women. Women who used any prescribed nitrosatable drug were more likely to have a stillbirth compared with unexposed women (aHRs 1.24; 95{\%} CI, 1.03-1.49). Conclusion: Nitrosatable drug use during the first 22 weeks of pregnancy might increase risk of stillbirth. The findings should be interpreted cautiously because of important unmeasured factors that might influence the observed association, including maternal vitamin C intake, dietary, and other sources of nitrate/nitrite intake.",
keywords = "amide, amine, N-nitroso compound, nitrosatable drug, pharmacoepidemiology, stillbirth",
author = "Thomsen, {Anne Marie L.} and Zeyan Liew and Riis, {Anders Hammerich} and Stayner, {Leslie Thomas} and Ramlau-Hansen, {Cecilia H{\o}st} and Torben Sigsgaard and J{\o}rn Olsen",
year = "2019",
month = "9",
day = "1",
doi = "10.1002/pds.4867",
language = "English",
volume = "28",
pages = "1204--1210",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "JohnWiley & Sons Ltd.",
number = "9",

}

RIS

TY - JOUR

T1 - Nitrosatable drug exposure during pregnancy and risk of stillbirth

AU - Thomsen, Anne Marie L.

AU - Liew, Zeyan

AU - Riis, Anders Hammerich

AU - Stayner, Leslie Thomas

AU - Ramlau-Hansen, Cecilia Høst

AU - Sigsgaard, Torben

AU - Olsen, Jørn

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Purpose: Nitrosatable drugs can react with nitrite in the stomach and form N-nitroso compounds. Exposure to nitrosatable drugs has been associated with congenital malformations and preterm birth, but use during pregnancy as a cause of fetal death is not well-known. We examined if prenatally nitrosatable drug use is associated with risk of stillbirth. Methods: A nationwide cohort was conducted using 554 844 women with singleton and first recorded pregnancies regardless of previous pregnancy history from the Danish Medical Birth Register from 1996 to 2015. Exposure was recorded by use of the Danish National Prescription Register and defined as women who had redeemed a prescribed nitrosatable drug in the first 22 weeks of pregnancy. The reference group was women with no redeemed prescribed nitrosatable drug in this time period. We categorized nitrosatable drugs as secondary amines, tertiary amines, and amides. Cox hazard regression was used to estimate crude and adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) for stillbirth. Results: Among the 84 720 exposed women, 348 had a stillbirth compared with 1690 stillbirths among the 470 124 unexposed women. Women who used any prescribed nitrosatable drug were more likely to have a stillbirth compared with unexposed women (aHRs 1.24; 95% CI, 1.03-1.49). Conclusion: Nitrosatable drug use during the first 22 weeks of pregnancy might increase risk of stillbirth. The findings should be interpreted cautiously because of important unmeasured factors that might influence the observed association, including maternal vitamin C intake, dietary, and other sources of nitrate/nitrite intake.

AB - Purpose: Nitrosatable drugs can react with nitrite in the stomach and form N-nitroso compounds. Exposure to nitrosatable drugs has been associated with congenital malformations and preterm birth, but use during pregnancy as a cause of fetal death is not well-known. We examined if prenatally nitrosatable drug use is associated with risk of stillbirth. Methods: A nationwide cohort was conducted using 554 844 women with singleton and first recorded pregnancies regardless of previous pregnancy history from the Danish Medical Birth Register from 1996 to 2015. Exposure was recorded by use of the Danish National Prescription Register and defined as women who had redeemed a prescribed nitrosatable drug in the first 22 weeks of pregnancy. The reference group was women with no redeemed prescribed nitrosatable drug in this time period. We categorized nitrosatable drugs as secondary amines, tertiary amines, and amides. Cox hazard regression was used to estimate crude and adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) for stillbirth. Results: Among the 84 720 exposed women, 348 had a stillbirth compared with 1690 stillbirths among the 470 124 unexposed women. Women who used any prescribed nitrosatable drug were more likely to have a stillbirth compared with unexposed women (aHRs 1.24; 95% CI, 1.03-1.49). Conclusion: Nitrosatable drug use during the first 22 weeks of pregnancy might increase risk of stillbirth. The findings should be interpreted cautiously because of important unmeasured factors that might influence the observed association, including maternal vitamin C intake, dietary, and other sources of nitrate/nitrite intake.

KW - amide

KW - amine

KW - N-nitroso compound

KW - nitrosatable drug

KW - pharmacoepidemiology

KW - stillbirth

UR - http://www.scopus.com/inward/record.url?scp=85070216263&partnerID=8YFLogxK

U2 - 10.1002/pds.4867

DO - 10.1002/pds.4867

M3 - Journal article

VL - 28

SP - 1204

EP - 1210

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 9

ER -